<?xml version="1.0" encoding="UTF-8"?>
<p>The reposition of CQ and HCQ as antiviral candidates for COVID-19 treatment was based on several in vitro and in vivo studies that reported their therapeutic effect against several coronaviruses, such as human OC43, SARS-CoV, and MERS-CoV [
 <xref rid="B81-jcm-09-02084" ref-type="bibr">81</xref>,
 <xref rid="B85-jcm-09-02084" ref-type="bibr">85</xref>]. The molecular mechanism of action of CQ and HCQ has not been fully elucidated yet [
 <xref rid="B82-jcm-09-02084" ref-type="bibr">82</xref>].
</p>
